FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy

Abstract Our aim was to analyse whether biomarkers extracted from baseline 18F-FDG PET before anti-PD1 treatment contribute to prognostic survival information for early risk stratification in metastatic melanoma. Fifty-six patients, without prior systemic treatment, BRAF wild type, explored using 18...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A. Flaus, V. Habouzit, N. De Leiris, J. P. Vuillez, M. T. Leccia, J. L. Perrot, N. Prevot, F. Cachin
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f670e00483354b05be876dfe62c9c6da
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f670e00483354b05be876dfe62c9c6da
record_format	dspace
spelling	oai:doaj.org-article:f670e00483354b05be876dfe62c9c6da2021-12-02T18:48:03ZFDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy10.1038/s41598-021-98310-32045-2322https://doaj.org/article/f670e00483354b05be876dfe62c9c6da2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98310-3https://doaj.org/toc/2045-2322Abstract Our aim was to analyse whether biomarkers extracted from baseline 18F-FDG PET before anti-PD1 treatment contribute to prognostic survival information for early risk stratification in metastatic melanoma. Fifty-six patients, without prior systemic treatment, BRAF wild type, explored using 18F-FDG PET were included retrospectively. Our primary endpoint was overall survival (OS). Total metabolic tumoral volume (MTV) and forty-one IBSI compliant parameters were extracted from PET. Parameters associated with outcome were evaluated by a cox regression model and when significant helped build a prognostic score. Median follow-up was 22.1 months and 21 patients died. Total MTV and long zone emphasis (LZE) correlated with shorter OS and served to define three risk categories for the prognostic score. For low, intermediate and high risk groups, survival rates were respectively 91.1% (IC 95 80–1), 56.1% (IC 95 37.1–85) and 19% (IC 95 0.06–60.2) and hazard ratios were respectively 0.11 (IC 95 0.025–0.46), P = 0.0028, 1.2 (IC 95 0.48–2.8), P = 0.74 and 5.9 (IC 95 2.5–14), P < 0.0001. To conclude, a prognostic score based on total MTV and LZE separated metastatic melanoma patients in 3 categories with dramatically different outcomes. Innovative therapies should be tested in the group with the lowest prognosis score for future clinical trials.A. FlausV. HabouzitN. De LeirisJ. P. VuillezM. T. LecciaJ. L. PerrotN. PrevotF. CachinNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q A. Flaus V. Habouzit N. De Leiris J. P. Vuillez M. T. Leccia J. L. Perrot N. Prevot F. Cachin FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
description	Abstract Our aim was to analyse whether biomarkers extracted from baseline 18F-FDG PET before anti-PD1 treatment contribute to prognostic survival information for early risk stratification in metastatic melanoma. Fifty-six patients, without prior systemic treatment, BRAF wild type, explored using 18F-FDG PET were included retrospectively. Our primary endpoint was overall survival (OS). Total metabolic tumoral volume (MTV) and forty-one IBSI compliant parameters were extracted from PET. Parameters associated with outcome were evaluated by a cox regression model and when significant helped build a prognostic score. Median follow-up was 22.1 months and 21 patients died. Total MTV and long zone emphasis (LZE) correlated with shorter OS and served to define three risk categories for the prognostic score. For low, intermediate and high risk groups, survival rates were respectively 91.1% (IC 95 80–1), 56.1% (IC 95 37.1–85) and 19% (IC 95 0.06–60.2) and hazard ratios were respectively 0.11 (IC 95 0.025–0.46), P = 0.0028, 1.2 (IC 95 0.48–2.8), P = 0.74 and 5.9 (IC 95 2.5–14), P < 0.0001. To conclude, a prognostic score based on total MTV and LZE separated metastatic melanoma patients in 3 categories with dramatically different outcomes. Innovative therapies should be tested in the group with the lowest prognosis score for future clinical trials.
format	article
author	A. Flaus V. Habouzit N. De Leiris J. P. Vuillez M. T. Leccia J. L. Perrot N. Prevot F. Cachin
author_facet	A. Flaus V. Habouzit N. De Leiris J. P. Vuillez M. T. Leccia J. L. Perrot N. Prevot F. Cachin
author_sort	A. Flaus
title	FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
title_short	FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
title_full	FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
title_fullStr	FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
title_full_unstemmed	FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
title_sort	fdg pet biomarkers for prediction of survival in metastatic melanoma prior to anti-pd1 immunotherapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f670e00483354b05be876dfe62c9c6da
work_keys_str_mv	AT aflaus fdgpetbiomarkersforpredictionofsurvivalinmetastaticmelanomapriortoantipd1immunotherapy AT vhabouzit fdgpetbiomarkersforpredictionofsurvivalinmetastaticmelanomapriortoantipd1immunotherapy AT ndeleiris fdgpetbiomarkersforpredictionofsurvivalinmetastaticmelanomapriortoantipd1immunotherapy AT jpvuillez fdgpetbiomarkersforpredictionofsurvivalinmetastaticmelanomapriortoantipd1immunotherapy AT mtleccia fdgpetbiomarkersforpredictionofsurvivalinmetastaticmelanomapriortoantipd1immunotherapy AT jlperrot fdgpetbiomarkersforpredictionofsurvivalinmetastaticmelanomapriortoantipd1immunotherapy AT nprevot fdgpetbiomarkersforpredictionofsurvivalinmetastaticmelanomapriortoantipd1immunotherapy AT fcachin fdgpetbiomarkersforpredictionofsurvivalinmetastaticmelanomapriortoantipd1immunotherapy
_version_	1718377658391199744

FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy

Ejemplares similares